Table 2 Safety after mirabegron treatment (n = 41)
From: Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study)
Baseline | Week 4 | Week 8 | Week 12 | |
|---|---|---|---|---|
Heart rate (beats/min) | 64 (57–73) | 63.5 (58–77) | ||
QTcF (ms) | 419 (397.25–438) | 415 (401.25–433.25) | ||
MMSE | 27 (25–28) | 26.5 (24.25–29) | 28 (26–29) | 27 (26–29.5) |
VES-13 | 6 (3–8) | 5 (4–7) | 4# (2–5.25) | 3* (2.25–6) |
VES-13 excluding age | 3.5 (1–6) | 3 (1–6) | 1# (1–3) | 1# (1–4) |